Human blood protein that was engineered to capture CTCs may be used as a cancer diagnostic.
After Type A meeting with FDA, company ends rights agreement with Ipsen, concludes no partners "in any region of the world" can be found for MCNA short-term
Study in JCI observed that TGF-beta-1 increased expression of the protein, which decreased p53 activity.
In a talk at the ASHG annual conference, Stephen Kingsmore presented his vision for enhancing and expediting the pipeline.
Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell line is derived from...
The buyer, Dutch generics giant Aspen Group, looks to broaden offerings, global operations
Abbott has extended an agreement to market BioGenex’ Xmatrx® platform for the automation of its FISH product line. Under the terms of the agreement, BioGenex will receive a multiyear minimum volume commitment from Abbott. The...
Institute will manufacture DCVax-L for Phase III trials and compassionate use.
Biochemists implement computer-based protein design strategy inspired by evolution, confirm structural features in the laboratory